title: NK cells prevalence, subsets and function in viral hepatitis C.
abstract: Innate immunity appears to play an important role in the pathogenesis of viral hepatitis C. Among various cell subsets of this immunity natural killer (NK) cells raised particular interest. These cells are abundant in liver, possess significant cytotoxic potential and show links with adaptive immunity. They play important role, particularly in the acute phase of viral infections, including hepatitis C. They exhibit various types of receptors, either inhibitory or activating, that are able to react with distinct ligands on infected cells. Homozygosity of some receptors, namely KIR2DL3 reacting with recipient HLA-C1 antigens is a herald of good prognosis in hepatitis C virus (HCV) infection. In the early stage of the latter, both the prevalence and the cytotoxicity of NK cells are increased. Their inhibitory receptors are down regulated whereas activating ones are up regulated. Interferon-γ secreted by NK56(+bright) NK cells has a direct cytotoxic effect on infected hepatocytes. In contrast, in the chronic phase of HCV liver disease both, the prevalence and function of NK cells are impaired. Nevertheless, their cytotoxicity contributes to liver injury. Cells show change in the polarization profile from NK1 to NK2, manifested by secretion of immunosuppressive cytokines. Some HCV peptides are inhibitory for NK cells leading to the reduction of their antiviral activity. The unwanted effects of HCV peptides can be at least partly reversed by the antiviral therapy.
authors.affiliation: Chair and Department of Clinical Immunology, University of Medical Sciences, Rokietnicka 5D, 60-806, Poznan, Poland. jzeromski@ump.edu.pl
authors.forename: Jan
authors.initials: J
authors.lastname: Zeromski
authors.forename: Iwona
authors.initials: I
authors.lastname: Mozer-Lisewska
authors.forename: Mariusz
authors.initials: M
authors.lastname: Kaczmarek
authors.forename: Arleta
authors.initials: A
authors.lastname: Kowala-Piaskowska
authors.forename: Jan
authors.initials: J
authors.lastname: Sikora
mesh_terms: D056704:Adaptive Immunity / Q000276:immunology; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D003602:Cytotoxicity, Immunologic; D004268:DNA-Binding Proteins / Q000276:immunology; D016654:Genes, RAG-1 / Q000276:immunology; D015236:HLA-C Antigens / Q000235:genetics / Q000378:metabolism*; D016174:Hepacivirus / Q000276:immunology / Q000378:metabolism; D006526:Hepatitis C / Q000188:drug therapy / Q000276:immunology*; D022781:Hepatocytes / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D007113:Immunity, Innate / Q000276:immunology*; D016898:Interferon-alpha / Q000627:therapeutic use; D007371:Interferon-gamma / Q000378:metabolism; D018664:Interleukin-12 / Q000627:therapeutic use; D019409:Interleukin-15 / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology* / Q000378:metabolism / Q000821:virology; D008099:Liver / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D016131:Lymphocyte Subsets / Q000276:immunology* / Q000378:metabolism / Q000821:virology; D051379:Mice; D011379:Prognosis; D054344:Receptors, KIR2DL3 / Q000235:genetics / Q000378:metabolism*; D012254:Ribavirin / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D004268:DNA-Binding Proteins; D015236:HLA-C Antigens; D016898:Interferon-alpha; D019409:Interleukin-15; D054344:Receptors, KIR2DL3; C064655:V(D)J recombination activating protein 2; D018664:Interleukin-12; D012254:Ribavirin; D007371:Interferon-gamma